Clinical trials: Zoledronic acid, completed
Cancer Prostate
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
The objective of the study is to investigate whether blood markers can be used to predict the development of bone metastases and to assess the efficacy and safety of zoledronic acid in cancer treatment induced bone loss.
- Trial name
- NCT00172055
- Testing
- Zoledronic acid
- Where
- 19 sites in Belgium
- Volunteers
- 218 people
- Sponsor
- Novartis Pharmaceuticals
Spinal Cord Injury
Zoledronic Acid in Acute Spinal Cord Injury
Maintenance of bone mass following spinal cord injury (SCI) is essential to fracture prevention and the associated morbidity of bed rest and further secondary complications.
- Trial name
- NCT01642901
- Testing
- Zoledronic acid, normal saline 0.9%
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Thomas Jefferson University
Avascular Necrosis of Femoral Head
Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head
The purpose of this study is to test the effect of zoledronic acid over 2 years in preventing early collapse and progression of joint dome depression (≥ 2 mm by X-ray) of the femoral head in patients with large (> 30%: criteria…
- Trial name
- EZAPCOFH (NCT00939900)
- Testing
- zoledronic acid (aclasta)
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Seoul National University Bundang Hospital
Multiple Myeloma Bone Disease
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
This study has two portions, a phase I portion and a phase II portion. The purpose of the phase I portion is to assess the maximum-tolerated dose (MTD) and to characterize dose limiting toxicity (DLT) of escalating doses of…
- Trial name
- NCT00741377
- Testing
- BHQ880, Zoledronic acid
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Hip Fractures, Osteoporosis
Zoledronate Early to Hip Fracture Patients - Safe and Effective?
To prevent hip fracture patients for having another fracture, secondary fracture preventing medication should be given as soon as possible.
- Trial name
- ZEBRA (NCT05025293)
- Testing
- Zoledronic Acid 5Mg/Bag 100Ml Inj, sodium chloride
- Where
- Norway
- Volunteers
- 228 people
- Sponsor
- Lene Bergendal Solberg
Osteoporosis
Study to Investigate the Efficacy and Safety After Administration of Daewoong Zoledronic Acid for the Purpose of Treatment or Prevention of Osteoporosis
This study is a non-interventional observational study. On the baseline (Visit 1), we collect demographic data from all participating subjects according to their daily medical conditions, prescribe drugs and collect validity and…
- Trial name
- NCT05614778
- Testing
- Zoledronic Acid injection, 5mg/100mL
- Where
- South Korea
- Volunteers
- 2,881 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Paget's Disease of Bone
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
The primary objective of this core study was to show non-inferiority of zoledronic acid to risedronate, with respect to the proportion of patients who achieved therapeutic response.
- Trial name
- NCT00103740
- Testing
- zoledronic acid, Risedronate, Calcium and vitamin D supplements
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer, Bone Metastases
Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates
A multicenter Prospective Study to assess the screening methods, parameter of NTX and the efficacy and safety of zoledronic acid treatment in addition to anti-tumor therapy in patients of non-small cell cancer with bone…
- Trial name
- BLEST (NCT00765687)
- Testing
- bisphosphates
- Where
- China
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Multiple Myeloma and Plasma Cell Neoplasm, Pain
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to cancer cells and not harm normal cells.
- Trial name
- NCT00482378
- Testing
- Pamidronate, Zoledronic acid, Sm 153 lexidronam
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Mayo Clinic
Non-Small-Cell Lung Cancer
A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
30-40% of patients with lung cancer will develop bone metastases during the course of their disease, which can lead to pain, decreased mobility and skeletal complications.
- Trial name
- NCT00172042
- Testing
- Zoledronic acid 4 mg
- Where
- 69 sites in Belgium, China and 13 more
- Volunteers
- 437 people
- Sponsor
- Novartis Pharmaceuticals
Paget's Disease of Bone
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
The core study looked at the effect of Zoledronic Acid given once as an intravenous (i.v.) infusion compared to 60 days of oral Risedronate in patients with Paget's disease of bone.
- Trial name
- NCT00051636
- Testing
- Zoledronic Acid, Risedronate, Calcium and Vitamin D
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 172 people
- Sponsor
- Novartis Pharmaceuticals
Pain, Neoplasm Metastasis
Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions
It is the aim of this multicentric clinical study to assess the efficacy and tolerability of zoledronic acid in combination with radiotherapy in patients with advanced osteolytic bone lesions in terms of the reduction of pain and…
- Conditions
- Pain, Neoplasm Metastasis, Cancer
- Trial name
- NCT00171964
- Testing
- Zoledronic acid in combination with therapy
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Zoledronate in Treating Bone Marrow Micrometastases in Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Zoledronate may delay or prevent bone marrow metastases in patients with breast cancer. PURPOSE: This phase II trial is studying how well zoledronate works in treating bone marrow micrometastases in women with stage I…
- Trial name
- NCT00295867
- Testing
- Zoledronic Acid
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of California, San Francisco
Spinal Cord Injury, Acute Spinal Cord Injury
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
The overall objective of this study is to define an effective therapeutic approach, using currently available medication, to prevent or mitigate the loss of bone mass and bone strength that occurs after acute spinal cord injury.
- Conditions
- Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
- Trial name
- NCT02325414
- Testing
- Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Pain
Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metastases-related Pain in Patients With Prostate Cancer
This study will evaluate the efficacy and safety of 4 mg zoledronic acid administered intravenously every 3-4 weeks in the treatment of bone metastases-related pain in patients with prostate cancer.
- Trial name
- TRAPEZE (NCT00375648)
- Testing
- Zoledronic acid
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration
Zoledronic Acid as Adjuvant Therapy in Neovascular Age-related Macular Degeneration (Z-AMD)
A pilot study of zoledronic acid as adjuvant therapy to standard anti-vascular endothelial growth factor (anti-VEGF) treatment for neovascular age-related macular degeneration (AMD).
- Trial name
- Z-AMD (NCT04304755)
- Testing
- Zoledronic Acid 5 MG in 5 ML Injection
- Where
- 2 sites in Norway
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Osteoporosis, Postmenopausal
MAGnesium Effect With ANtiosteoporotic Drugs
Randomized pilot clinical trial to demonstrate superiority of bisphosphonate-magnesium combination over bisphosphonates alone in postmenopausal osteoporosis in slowing bone remodeling as assessed by C-terminal telopeptide of bone…
- Trial name
- MAGELLAN (NCT05328154)
- Testing
- Follow-up of patients with postmenopausal osteoporosis, with or without fractures, requiring initiation of injectable bisphosphonate therapy as part of their usual care, Follow-up of patients with postmenopausal osteoporosis, fractured or not, requiring initiation of injectable bisphosphonate therapy as part of care with magnesium supplementation
- Where
- France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Clermont-Ferrand
Multiple Myeloma
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
This study evaluated the effectiveness and safety of a dosing method for zoledronic acid in preventing skeletal complications in multiple myeloma participants who have been on an intravenous (IV) bisphosphonate for about one to…
- Trial name
- Z-MARK (NCT00622505)
- Testing
- zoledronic acid
- Where
- 42 sites in United States
- Volunteers
- 121 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis
Denosumab is an antibody against receptor-activator of nuclear factor kappa-B ligand that prevents recruitment and differentiation of mature osteoclasts.
- Trial name
- ZOLARMAB (NCT03087851)
- Testing
- Zoledronic Acid
- Where
- Denmark
- Volunteers
- 61 people
- Sponsor
- Aarhus University Hospital
Breast Cancer
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
The purpose of this study is to determine whether zoledronic acid given intravenously every 6 months can prevent reduction in bone mineral density in women with early stage breast cancer receiving adjuvant therapy with the…
- Trial name
- NCT00376740
- Testing
- zoledronic acid
- Where
- 2 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Soroka University Medical Center